Evidence map›Paper›PMID 29624474›Full record

ReviewHuman vaccines & immunotherapeutics2018

Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.

Rika Nakahashi-Ouchida, Yoshikazu Yuki, Hiroshi Kiyono

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rika Nakahashi-Ouchidaa Division of Mucosal Immunology, Department of Microbiology and Immunology , Institute of Medical Science, University of Tokyo , Tokyo , Japan.
Yoshikazu Yukia Division of Mucosal Immunology, Department of Microbiology and Immunology , Institute of Medical Science, University of Tokyo , Tokyo , Japan.
Hiroshi Kiyonoa Division of Mucosal Immunology, Department of Microbiology and Immunology , Institute of Medical Science, University of Tokyo , Tokyo , Japan.
The University of Tokyo · JPChiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mucosal surfaces of the respiratory and gastrointestinal tracts are continuously exposed to countless beneficial and pathologic antigens. These mucosal surfaces are thus equipped with an immune system that is unique from those elsewhere in the body; this unique system provides the first line of immune surveillance and defense against pathogen invasion. The sophisticated immune induction machinery in the aero-digestive tract involves mucosa-associated lymphoid tissues, including nasopharyngeal- and gut-associated lymphoid tissues, for the generation of antigen-specific humoral and cellular immune responses. Consequently, nasal or oral immunization with an appropriate vaccine delivery vehicle prompts the induction of protective immunity in both the mucosal and systemic compartments, leading to a double layer of protection against pathogens. To harness the benefits of mucosal vaccines, various mucosal antigen delivery vehicles are under development, and a cationic cholesteryl-group-bearing pullulan nanogel (cCHP nanogel) has emerged as a potent nasal vaccine delivery system for the induction of protective immunity against respiratory infections.

Indexed as

Administration, IntranasalDrug CarriersGlucansHumansNanogelsPolyethylene GlycolsPolyethyleneimineRespiratory Tract InfectionsVaccinesDrug CarriersGlucansNanogelspolyethylene glycol polyethyleneimine nanogelPolyethylene GlycolsPolyethyleneiminepullulanVaccinesadjuvantdrug delivery systemmucosal immune responsenasal vaccinesafety

Identifiers

PMID29624474
PMCPMC6183202
OpenAlexW2796134861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.